BIO-B — BIO-RAD LABORATORIES, INC.
—
NYSE ·
Unknown ·
Unknown ·
CIK 12208 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 656,400,000 | 328,600,000 | 100,000 | 458,600,000 | 10,783,100,000 | 465,300,000 | 3,180,100,000 |
| Jun 2026 | 651,000,000 | 345,800,000 | 72,600,000 | 371,400,000 | 10,252,000,000 | 517,000,000 | 3,078,100,000 |
| Mar 2026 | 592,100,000 | 309,400,000 | 34,100,000 | -527,100,000 | 9,790,000,000 | 507,200,000 | 2,938,700,000 |
| Dec 2025 | 693,200,000 | 345,200,000 | 53,900,000 | 720,000,000 | 10,576,500,000 | 529,800,000 | 3,122,900,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$468,100,000
Investing CF
$-340,000,000
Financing CF
$-69,900,000
CapEx
$-139,000,000
Dividends Paid
—
Buybacks
$-79,300,000
EPS Diluted TTM
$37.97
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$8,479,200,000
Inventory
$783,900,000
Receivables
$422,600,000
ST Investments
$1,199,000,000
EBIT TTM
$1,369,000,000
Pretax Income TTM
$1,320,200,000
Interest Exp TTM
$48,800,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,592,699,904
EBITDA
$410,900,000
Free Cash Flow
$271,649,984
Enterprise Value
$9,904,972,800
Total Cash
$1,664,300,032
Total Debt
$1,363,399,936
Shares Out
5,060,815
Trailing EPS
$37.64
Book Value
$282.74
ROE
14.3%
ROA
1.5%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,583,200,000 | 218,600,000 | 759,900,000 | 10,576,500,000 | 3,122,900,000 | 7,453,600,000 | 532,200,000 |
| Dec 2024 | 2,566,500,000 | 269,000,000 | -1,844,200,000 | 9,364,100,000 | 2,794,800,000 | 6,569,300,000 | 455,200,000 |
| Dec 2023 | 2,671,200,000 | 337,800,000 | -637,300,000 | 12,299,100,000 | 3,557,900,000 | 8,741,200,000 | 374,900,000 |
| Dec 2022 | 2,802,200,000 | 475,100,000 | -3,627,500,000 | 13,501,666,000 | 3,886,414,000 | 9,615,252,000 | 194,400,000 |
TTM Snapshot
Revenues TTM
$2,589,300,000
NetIncome TTM
$222,400,000
OpCashFlow TTM
—
Assets (Latest)
$10,252,000,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC. | $254.47B | $686.79 | — |
| IBM | INTERNATIONAL BUSINESS MACHINES CORP | $218.41B | $231.09 | — |
| KLAC | KLA CORP | $188.36B | $144.56 | — |
| DHR | DANAHER CORP /DE/ | $158.71B | $225.77 | — |
| LMT | LOCKHEED MARTIN CORP | $136.37B | $590.34 | — |
News headlines (Yahoo Finance, 1h cache)
2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox
2026-11-13 14:33 · Yahoo
Cell Lysis / Cell Fractionation - Global Strategic Business Report 2026: Capture the $4.5 Billion Market by 2032 | Features Competitive Intelligence on Thermo Fisher, Beckman Coulter, Bio-Rad, Qiagen
2026-11-12 15:00 · Yahoo
Microfluidic Device Systems - Global Strategic Business Report 2026: Capitalize on 8.7% CAGR to $11.1 Billion by 2032 | Abbott, Danaher, Bio-Rad, and Siemens Healthineers Shape the Competition
2026-11-12 14:57 · Yahoo
Is Illumina Stock Worth The Wait?
2026-11-11 15:29 · Yahoo
Transfection Technologies - Global Strategic Business Report 2026: Capitalize on a $2.5 Billion Market by 2032 as Thermo Fisher, Lonza, Bio-Rad, Qiagen and MilliporeSigma Accelerate
2026-11-11 14:21 · Yahoo
Single-Cell Analysis - Global Strategic Business Report 2026: Capitalize on 20.4% CAGR as Illumina, Thermo Fisher Scientific, Bio-Rad and Agilent Battle for Shares in the $26.1 Billion Market by 2032
2026-11-11 14:18 · Yahoo
Molecular Cytogenetics - Global Strategic Business Report: Capitalize on 8.8% CAGR to US$3.5 Billion by 2030; Outmaneuver Abbott, Agilent, Bio-Rad, Illumina and Roche Amid Tariff Shifts
2026-11-11 14:13 · Yahoo
Capillary Electrophoresis - Global Strategic Business Report: Secure Share of the $1.1 Billion Market by 2032 as Agilent, Bio-Rad, Danaher and Thermo Fisher Accelerate CE-MS Innovation
2026-11-10 15:11 · Yahoo
Nucleic Acid Isolation and Purification - Global Strategic Business Report: Capture the $3.9 Billion Revenue Surge by 2030 as Thermo Fisher, Qiagen, Danaher, Illumina, and Bio-Rad Battle for Share
2026-11-10 15:02 · Yahoo
Gene Amplification Technologies - Global Strategic Business Report: Capture $4.4B in New Revenue by 2030 as Abbott, Bio-Rad, bioMerieux, Cepheid and Becton Dickinson Battle for Share
2026-11-10 14:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.